Drug Trial News

RSS

Children with polyarticular JIA benefit from early and aggressive therapy

Children with juvenile arthritis who are treated early and aggressively have better outcomes, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

Final results from Vertex VX-509 Phase 2a study on RA

Vertex Pharmaceuticals Incorporated today announced the final results from a Phase 2a study of the investigational selective oral JAK3 inhibitor VX-509.

6 Nov 2011

New data from Santaris Pharma miravirsen Phase 2a trial on HCV

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, presents new data from the Phase 2a trial showing that miravirsen given as a four-week monotherapy treatment provided robust dose-dependent anti-viral activity with a mean reduction of 2 to 3 logs from baseline in HCV RNA (log10 IU/mL) that was maintained for more than four weeks beyond the end of therapy.

6 Nov 2011

Cystic fibrosis drug shows promise in trial

The latest clinical trial in its later advanced stags found that oral drug ivacaftor (VX-77) provides major, sustained improvement in lung function, growth and other signs and symptoms for a subset of cystic fibrosis patients.

6 Nov 2011

Human Genome Sciences to present abstracts regarding BENLYSTA, SLE at ACR/ARHP meeting

Human Genome Sciences, Inc. announced today that several abstracts related to BENLYSTA (belimumab) and systemic lupus erythematosus will be presented at the annual meeting of the American College of Rheumatology/ Association of Rheumatology Health Professionals, being held in Chicago, IL from November 4 to November 9, 2011.

5 Nov 2011

Sunovion reports positive results from ciclesonide nasal aerosol Phase III study for perennial allergic rhinitis

Sunovion Pharmaceuticals Inc. today announced results from a large Phase III clinical study of ciclesonide nasal aerosol, a corticosteroid formulated with a hydrofluoroalkane (HFA) propellant, intended for the treatment of allergic rhinitis.

5 Nov 2011

Presidio Pharmaceuticals advances with its HCV antiviral drug discovery, development programs

Presidio Pharmaceuticals, Inc. today announced progress with its HCV antiviral drug discovery and development programs. A primary company objective is to advance multiple potent and safe inhibitors that target multiple HCV proteins and provide pan-genotypic coverage, as we believe such combination therapies will more adequately address the global medical need in the future.

5 Nov 2011

Results of Phase 2 program to develop NSAIDs to be reported at ACR annual meeting

The results of the Phase 2 program sponsored by Iroko Pharmaceuticals to develop novel, lower-dose formulations of a widely used class of pain medicines will be reported November 7th at the annual meeting of the American College of Rheumatology in Chicago.

5 Nov 2011

SCRIP honors Glenmark for business excellence and innovative R & D capabilities

SCRIP, a leading global pharmaceutical and biotech news publication, honoured Glenmark with two global recognitions, for its business excellence and innovative R & D capabilities.

5 Nov 2011

Daily intake of Souvenaid improves memory in people with mild AD

A second clinical trial of the medical food Souvenaid confirmed that daily intake of the nutritional intervention improves memory in people with mild Alzheimer's disease.

5 Nov 2011

Rexahn announces results from Serdaxin Phase IIb trial on major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced results from its Phase IIb clinical trial of Serdaxin in major depressive disorder.

5 Nov 2011

Positive data from RegeneRx RGN-259 Phase 2 trial on dry eye syndrome

RegeneRx Biopharmaceuticals, Inc. today announced positive data from its 72-patient, Phase 2 clinical trial with RGN-259, a sterile, preservative-free eye drop, to evaluate its safety and efficacy for the treatment of signs and symptoms of dry eye syndrome over a treatment period of 30 days using the Controlled Adverse Environment (CAE) model.

5 Nov 2011

Inhibitex third quarter revenue increases to $1.3 million

Inhibitex, Inc. today announced its financial results for the third quarter ended September 30, 2011 and provided an update on several recent corporate developments, including top-line safety and antiviral data from the first cohort in its ongoing clinical trial designed to evaluate higher doses of INX-189, an oral nucleotide polymerase inhibitor, being developed to treat chronic infections caused by hepatitis C virus (HCV), administered as monotherapy or in combination with ribavirin for seven days.

4 Nov 2011

Jennerex commences enrollment in JX-594 Phase 2b trial for HCC

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, together with its international commercialization partners, today announced that enrollment has been initiated and the first patient has been randomized in a Phase 2b clinical trial called TRAVERSE.

4 Nov 2011

Final results from Vertex KALYDECO second of two Phase 3 studies on CF

Vertex Pharmaceuticals Incorporated today announced final results from the ENVISION study, the second of two pivotal Phase 3 studies of KALYDECO, a medicine in development that targets the defective protein that causes cystic fibrosis.

4 Nov 2011

Senesco commences dosing in SNS01-T Phase 1b/2a clinical study for multiple myeloma

Senesco Technologies, Inc. today announced the initiation of patient dosing in its Phase 1b/2a clinical study of SNS01-T at the Mayo Clinic in Rochester, MN. The study is an open-label, multiple-dose, dose-escalation study which will evaluate the safety and tolerability of SNS01-T when administered by intravenous infusion to relapsed or refractory multiple myeloma patients.

3 Nov 2011

Positive results from Clinuvel's US Phase II study of photoprotective drug, afamelanotide

Clinuvel Pharmaceuticals Limited, a global biopharmaceutical company with unique expertise on the interaction of light and human skin, today announced positive results of its first US Phase II study of the novel photoprotective drug afamelanotide, known as SCENESSE.

3 Nov 2011

Abbott to highlight latest research findings on HUMIRA at ACR annual meeting

Abbott scientists and independent researchers will highlight the latest research findings on HUMIRA (adalimumab) at this year's American College of Rheumatology (ACR) Annual Scientific Meeting, scheduled for November 5-9 in Chicago.

3 Nov 2011

Galectin Therapeutics forms Liver Fibrosis Clinical Trials Advisory Board

Galectin Therapeutics Inc., the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin receptors, today announced the formation of its Liver Fibrosis Clinical Trials Advisory Board comprised of key opinion leaders from Emory Hospital and School of Medicine, Massachusetts General Hospital and Harvard School of Medicine, University of Michigan Hospital and School of Medicine, Mount Sinai Hospital and School of Medicine, and University of Wisconsin Hospital and School of Medicine.

3 Nov 2011

FEIBA drug safe and effective for patients with hemophilia A

An international research team led by Dr. Cindy Leissinger of Tulane University School of Medicine, along with Dr. Alessandro Gringeri from the University of Milan, has found that a drug commonly used to treat bleeding events in people with a type of severe hemophilia can also be used to prevent such events from happening in the first place.

3 Nov 2011